News
Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy
- Author:
- Walter Alexander
Delayed count recovery remains a key safety concern.
News
Phase 1 study shows feasibility, safety, efficacy of STAR T cells for ALL
- Author:
- Walter Alexander
STAR (synthetic T-cell receptor and antigen receptor) T-cells were reported superior to CAR T cells for acute...
News
Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies
- Author:
- Walter Alexander
Once-daily oral DTRM-555 shows encouraging activity in Richter’s transformation and DLBCL.
News
Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab
- Author:
- Walter Alexander
Favorable MRD negativity and overall survival rates with low higher-grade toxicities suggest that reductions in...
News
Rechallenge ‘reasonable’ for some with small-cell lung cancer
- Author:
- Walter Alexander
Carboplatin plus etoposide significantly prolonged progression-free survival, compared with topotecan, in patients with advanced or relapsed,...
News
Geography and behaviors linked to early-onset colorectal cancer survival in U.S. women
- Author:
- Walter Alexander
Physical inactivity and lower fertility correlate modestly with early-onset colorectal cancer mortality in women.
News
Phase 1 study: Beta-blocker may improve melanoma treatment response
- Author:
- Walter Alexander
“It’s exciting that an extremely inexpensive drug like propranolol that could be used in every country around the world could have an impact on...
News
Fixed duration ibrutinib/venetoclax appears feasible for some CLL/SLL patients
- Author:
- Walter Alexander
After 12 cycles of ibrutinib/venetoclax, patients then randomized to placebo had 1-year disease-free survival of...
News
TNF inhibitor–induced psoriasis treatment algorithm maintains TNF inhibitor if possible
- Author:
- Walter Alexander
TNFI-induced psoriasis improved or resolved with topical medications alone in 63.5% of patients.
News
Adding cetuximab to afatinib provides no benefit in EGFR-mutant NSCLC
- Author:
- Walter Alexander
Survival outcomes were similar whether patients received afatinib alone or afatinib plus cetuximab.
News
No benefit with adjuvant sorafenib in intermediate-/high-risk RCC
- Author:
- Walter Alexander
Survival was similar with adjuvant sorafenib and placebo.
News
Baricitinib reduces adult atopic dermatitis severity in phase 3 study
- Author:
- Walter Alexander
In moderate to evere AD, baricitinib 4 mg on top of topical corticosteroids significantly reduced signs and symptoms.
News
Durable efficacy with MK-6482 in VHL-associated RCC
- Author:
- Walter Alexander
MK-6482 produced responses in patients with Von Hippel-Lindau disease-associated renal cell carcinoma and non-renal lesions.
News
Clinical factors and treatment tied to COVID-19 mortality in cancer patients
- Author:
- Walter Alexander
Analyses of CCC19 data revealed factors linked to mortality in patients with COVID-19 and cancer.
News
Apatinib plus gefitinib: Better PFS but more toxicity
- Author:
- Walter Alexander
Adding apatinib to gefitinib prolonged progression-free survival by 3.5 months.